Aceclidine for presbyopia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 7 registered trials.

Why this status

  1. 19 Dec 2022: Trial registered, NCT05656027
  2. 19 Dec 2022: Trial started, NCT05656027
  3. 15 Feb 2023: Trial registered, NCT05728944
  4. 21 Feb 2023: Trial started, NCT05753189
  5. 3 Mar 2023: Trial registered, NCT05753189
  6. 6 Mar 2023: Trial started, NCT05728944
  7. 21 Sep 2023: Trial registered, NCT06045299
  8. 27 Sep 2023: Trial started, NCT06045299

The trials

NCT05294328: Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia

State
Completed
Phase
Phase 2
People
68 taking part
Started
5 May 2022
Primary completion
22 Aug 2022
Arms
Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally
Results
Posted on the registry
  1. 24 Mar 2022: Trial registered
  2. 5 May 2022: Trial started
  3. 10 Sep 2022: Trial completed
  4. 5 Sep 2024: Trial results posted

NCT05431543: Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia

State
Completed
Phase
Phase 2
People
59 taking part
Started
6 Aug 2022
Primary completion
14 Dec 2022
Arms
Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally
Results
Posted on the registry
  1. 24 Jun 2022: Trial registered
  2. 6 Aug 2022: Trial started
  3. 14 Dec 2022: Trial completed
  4. 5 Sep 2024: Trial results posted

NCT05656027: Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia

State
Completed
Phase
Phase 3
People
469 taking part
Started
19 Dec 2022
Primary completion
15 Dec 2023
Arms
Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally
Results
Posted on the registry
  1. 19 Dec 2022: Trial registered
  2. 19 Dec 2022: Trial started
  3. 25 Jan 2024: Trial completed
  4. 25 Feb 2026: Trial results posted

NCT05728944: Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia

State
Completed
Phase
Phase 3
People
229 taking part
Started
6 Mar 2023
Primary completion
14 Dec 2023
Arms
Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally
Results
Posted on the registry
  1. 15 Feb 2023: Trial registered
  2. 6 Mar 2023: Trial started
  3. 24 Jan 2024: Trial completed
  4. 25 Feb 2026: Trial results posted

NCT05753189: Phase 3 Safety Study of LNZ100 and LNZ101 for the Treatment of Presbyopia Subjects

State
Completed
Phase
Phase 3
People
362 taking part
Started
21 Feb 2023
Primary completion
9 Feb 2024
Arms
Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally
Results
Posted on the registry
  1. 21 Feb 2023: Trial started
  2. 3 Mar 2023: Trial registered
  3. 9 Feb 2024: Trial completed
  4. 13 May 2026: Trial results posted

NCT06045299: Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia

State
Completed
Phase
Phase 3
People
300 taking part
Started
27 Sep 2023
Primary completion
19 Aug 2024
Arms
LNZ100 (Aceclidine) ophthalmic solution
Results
None posted
  1. 21 Sep 2023: Trial registered
  2. 27 Sep 2023: Trial started
  3. 27 Jan 2025: Trial completed

NCT06270030: Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia

State
Completed
Phase
Phase 1
People
21 taking part
Started
4 Mar 2024
Primary completion
10 Apr 2024
Arms
LNZ100 (Aceclidine) ophthalmic solution
Results
None posted
  1. 21 Feb 2024: Trial registered
  2. 4 Mar 2024: Trial started
  3. 10 Apr 2024: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Aceclidine ophthalmic solution, LNZ100 (Aceclidine) ophthalmic solution.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.